CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203284Orig1s000

CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

NDA	203-284	Submission Date(s)	December 23, 2011, February 22, March 13, March 27, April 20, June 29, July 03, July 05, August 23, 2012	
Brand Name		Ravicti®		
Generic Name		Glycerol phenylbutyrate		
Reviewer		Insook Kim, Ph.D.		
Team Leader		Sue-Chih Lee, Ph.D.		
Division Director		Capt. Edward D. Bashaw, Pharm.D.		
OCP Division		Division of Clinical Pharmacology 3		
OND Division		Division of Gastroenterology and Inborn Errors Products		
Sponsor		Hyperion		
Submission Type;		Original		

CLINICAL PHARMACOLOGY REVIEW ADDENDUM

Executive Summary

This is an addendum to the original clinical pharmacology review of NDA 203-284 dated 1/2/13 to discuss two post-marketing studies. We require a pharmacokinetic study in pediatric patients < 2 years old and recommend an in vivo drug interaction study with a sensitive CYP3A4 substrate as a post-marketing commitment as below.

Post-Marketing Requirement

Pharmacokinetic studies in pediatric patients from birth to less than 2 years of age with Urea Cycle Disorders. PK of glycerol phenylbutyrate and its metabolites (PBA, PAA and PAGN) must be characterized and the exposure-response relationship should be evaluated for safety and efficacy.

<u>Rationale</u>

DOCKE.

In the NDA, Ravicti was not studied in patients younger than 2 month old and very few data on patients in the age category of 2 months to 2 years were included. Because of no or insufficient data in patients younger than 2 years old, additional clinical studies will be required in these two age groups i.e. < 2 months old and 2 months to 2 years old.

In the age category of 2 months to 2 years, two of the four patients had PAA levels $\sim 500 \mu g/mL$ when on buphenyl or HPN-100. Therefore we recommend PK blood samples be collected to characterize PK of Ravicti and its metabolites, PBA, PAA and PAGN.

PAA toxicity with neurological and gastrointestinal manifestations has been demonstrated with IV administration of PAA. In cancer patients, the symptoms at PAA levels of \sim 500 µg/mL were somnolence, emesis and lethargy in patients with cancer who received IV PAA. More severe toxicity (confusion and psychomotor depression)

occurred in patients with mean peak PAA level of 682 μ g/mL¹. In patients with acute hyperammonemia, overdose of IV PAA in children has been reported to cause death and coma.² Levels of PAA in these children were > 1000 μ g/mL.

Post-Marketing Commitment

In vivo drug interaction study to evaluate the effect of Ravicti on a concomitant drug that is metabolized by CYP3A4.

The highest proposed dose of Ravicti should be used to maximize the potential of in vivo drug interaction while the dose for individual patients may vary.

<u>Rationale</u>: Based on the in vitro studies suggested drug interaction potential with substrates of three CYP enzymes, we are requesting one in vivo study with CYP3A.

The [I]/Ki of PBA was the highest for CYP2C9 i.e. 0.451 and it was 0.393 for CYP2D6 and [I]/IC₅₀ for CYP3A4 was 0.325. Although the [I]/Ki was higher for CYP2C9 than for CYP3A4, we recommend that in vivo drug interaction study with a sensitive substrate of CYP3A4/5 based on following:

- 1) The wider range of drugs that are metabolized by CYP3A4
- 2) The significant contribution of CYP3A4 to the metabolism in the intestine because phenylbutyrate, a metabolite of glycerol phenylbutyrate is presumably generated in the intestine.
- 3) Phenylacetate (PAA), which is converted from phenylbutyrate, showed an inhibitory effect on CYP3A4 and CYP2C9 at a concentration higher than the observed plasma concentrations. While the possibility of in vivo drug interaction with CYP2C9 substrate is unlikely based on the [I]/Ki of PAA for CYP2C9 determined in an additional study, the [I]/Ki of PAA for CYP3A4 was not determined. Therefore, potential effects PAA on CYP3A4 can not be ruled out.

DOCKE

¹ Thibault A et al, Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995;75:2932-8.

² Parphanphoj et al (2000), Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring the treatment of acute hyperammonemia, J. Inherit. Metab. Dis 23: 129-36.


This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

INSOOK KIM 01/18/2013

SUE CHIH H LEE 01/23/2013

EDWARD D BASHAW 01/23/2013



CLINICAL PHARMACOLOGY REVIEW

NDA	203-284	Submission Date(s)	December 23, 2011, February 22, March 13, March 27, April 20, June 29, July 03, July 05, August 23, 2012	
Brand No	ame	Ravicti®		
Generic Name		Glycerol phenylbutyrate		
Reviewer		Insook Kim, Ph.D.		
Team Leader		Sue-Chih Lee, Ph.D.		
PM Reviewer		Kevin Krudys, Ph.D.		
PM Team Leader		Nitin Mehrotra, Ph.D.		
OCP Division		Division of Clinical Pharmacology 3		
OND Division		Division of Gastroenterology and Inborn Errors Products		
Sponsor		Hyperion		
Submissi	on Type;	Original	505(b)(1)	
Formulation; Strengths; Regimen		 Liquid for oral administration 1.1 g of glycerol phenylbutyrate (GPB) in 1 ml of Ravicti® (equivalent to 1.02 g phenylbutyric acid) Recommended starting total daily dose is as below 		
		 Dose range: 4.5-11.2 ml/m² (5-12.4 g/m²) Not to exceed 17.5 ml (19 g) total Total daily dose should be administered in three divided doses with meals 		
Indicatio	on	Adjunctive therapy for chronic management of adult and pediatric patients with urea cycle disorders involving deficiencies of the following enzymes: Carbamyl phsphate synthetase (CPS), Ornithine transcarbamylase (OTC), Argininosuccinate synthetase (ASS), Argininosuccinate lyase (ASL), Arginase (ARG), Mitochondrial transporter ornithine translocase (HHH deficiency)		

Table of Contents

1	Exec	cutive Summary	2
		Recommendations	
	1.2	Phase IV Commitments	. 3
	1.3	Summary of Clinical Pharmacology and Biopharmaceutics Findings	. 3
2	Que	stion-Based Review	8
	2.1	General Attributes of the drug	. 8
		General Clinical Pharmacology	

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.